Valuation: Novacyt

Capitalization 32.01M 37.65M 29.96M 28.13M 51.83M 3.42B 56.63M 349M 135M 1.61B 141M 138M 5.85B P/E ratio 2025 *
-
P/E ratio 2026 * -
Enterprise value 22.39M 26.33M 20.95M 19.67M 36.25M 2.39B 39.6M 244M 94.4M 1.12B 98.79M 96.71M 4.09B EV / Sales 2025 *
0.99x
EV / Sales 2026 * 1.12x
Free-Float
96.82%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+5.34%
1 week-0.11%
Current month+4.73%
1 month+4.25%
3 months-1.84%
6 months-14.34%
Current year-24.58%
More quotes
1 week 0.43
Extreme 0.4305
0.46
1 month 0.42
Extreme 0.421
0.46
Current year 0.42
Extreme 0.4185
0.84
1 year 0.42
Extreme 0.4185
0.84
3 years 0.42
Extreme 0.4185
1.99
5 years 0.42
Extreme 0.4185
13.62
10 years 0.06
Extreme 0.0612
13.96
More quotes
Manager TitleAgeSince
Chief Executive Officer 52 2024-04-30
Director of Finance/CFO 43 2019-12-31
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 74 2006-07-02
Director/Board Member 58 2017-06-26
Director/Board Member 43 2024-01-01
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+5.34%-0.11%-33.82%-45.30% 35.67M
-1.39%+6.59%-24.82%+138.93% 1.07B
+4.72%+8.27% - - 806M
-3.44%+25.78%+221.45%+146.34% 402M
-10.98%-11.99%+119.63%+26.34% 95.68M
Average -1.15%+5.60%+70.61%+66.58% 481.86M
Weighted average by Cap. +0.03%+8.84%+45.40%+129.97%
See all sector performances

Financials

2025 *2026 *
Net sales 22.71M 26.7M 21.25M 19.95M 36.76M 2.42B 40.17M 248M 95.74M 1.14B 100M 98.08M 4.15B 26.1M 30.69M 24.42M 22.93M 42.25M 2.78B 46.16M 285M 110M 1.31B 115M 113M 4.77B
Net income - -
Net Debt -9.63M -11.32M -9.01M -8.46M -15.59M -1.03B -17.03M -105M -40.59M -483M -42.48M -41.58M -1.76B -2.68M -3.15M -2.5M -2.35M -4.33M -285M -4.73M -29.18M -11.28M -134M -11.8M -11.56M -488M
More financial data * Estimated data
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Employees
234
More about the company
Date Price Change Volume
25-12-15 0.4540 +5.34% 361,926
25-12-12 0.4310 0.00% 87,897
25-12-11 0.4310 -1.60% 22,950
25-12-10 0.4380 -2.23% 24,907
25-12-09 0.4480 +0.90% 79,096

Real-time Euronext Paris, December 15, 2025 at 11:55 am EST

More quotes

Annual profits - Rate of surprise